Photo Release -- Enzymotec Ltd. Awarded the Title of Outstanding Exporter for 2012

Outstanding Exporter for 2012

MIGDAL HA'EMEQ, Israel, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that it received the title of Outstanding Exporter for 2012 from the Israeli Ministry of Economy. Certificates and awards for Outstanding Exporter were presented to Enzymotec's CEO, Dr. Ariel Katz, and Vice President - Research and Development, Dr. Tzafra Cohen, by the President of Israel, Mr. Shimon Peres and the Minister of Economy, Mr. Naftali Bennett, at a ceremony held at the Presidential Residence in Jerusalem.

credit to: Josephe Angel

A photo accompanying this release is available at

Enzymotec received the award of Outstanding Exporter based on its notable growth in exports, as part of the Company's successful strategy to grow international sales.

"We are honored to receive this award, which underlines our continuous business success and growing demand for our products," said Dr. Ariel Katz, President and Chief Executive Officer of Enzymotec Ltd. "This recognition is a result of a true team effort and I want to thank all of our employees for their hard work and dedication. We are very proud to be one of the leading suppliers of nutritional products and we look forward to expanding our global customer base."

About Enzymotec Ltd.

Enzymotec Ltd. is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit

Forward Looking Statement

This release may contain forward-looking statements, which express the current beliefs and expectations of Enzymotec's management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences the following risks: a high proportion of the sales of our InFat product is sold to end users by a single company in China; we rely on our Swedish joint venture partner to manufacture InFat, and certain matters related to the joint venture are the subject of disagreement; our gross profits may be adversely affected if we are only able to obtain lower quality krill meal; our ability to obtain krill may be affected by conservation regulation or initiatives; we are dependent on a single facility that houses the majority of our operations; we may not be able to expand our production or processing capabilities or satisfy growing demand; our product development cycle is lengthy and uncertain, and our development or commercialization efforts for our products may be unsuccessful; we are subject to significant and increasing government regulations regarding the sale and marketing of our products; we may not be able to protect our proprietary technology or prevent its unauthorized use by third parties; we are currently subject to litigation, and in the future may become subject to additional litigation, regarding intellectual property rights; and other factors discussed under the heading "Risk Factors" in Enzymotec's final prospectus for its initial public offering filed with the Securities and Exchange Commission on September 30, 2013. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and Enzymotec undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

The photo is also available via AP PhotoExpress.

CONTACT: ICR, LLC Katie Turner 646-277-1228 -or- John Mills 310-954-1105 John.Mills@icrinc.comSource:Enzymotec Ltd.